Compounds and methods for modulating activation of NF-κB

Details Compounds and methods for modulating activation of NF-κB Compounds and methods for modulating activation of NF-κB

2007-01-25

2008-08-19

Slobodyansky, Elizabeth (Department: 1652)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023500, C435S183000

Reexamination Certificate

active

07414120

ABSTRACT:
Compositions and methods for modulating the activation of nuclear factor κB (NF-κB) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated IκBα and/or IκBβ. Such compositions may be used for treating diseases associated with NF-κB activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.

REFERENCES:
patent: 5126324 (1992-06-01), Clark
patent: 5519003 (1996-05-01), Mochly-Rosen et al.
patent: 5597898 (1997-01-01), Ghosh
patent: 5849580 (1998-12-01), Ghosh
patent: 5851812 (1998-12-01), Goeddel
patent: 5916760 (1999-06-01), Goeddel
patent: 5932425 (1999-08-01), Alkalay et al.
patent: 5939302 (1999-08-01), Goeddel
patent: 5972674 (1999-10-01), Mercurio
patent: 6235492 (2001-05-01), Rothe
patent: 6235512 (2001-05-01), Rothe
patent: 6235513 (2001-05-01), Rothe
patent: 6242253 (2001-06-01), Karin
patent: 6258579 (2001-07-01), Mercurio
patent: 6410516 (2002-06-01), Baltimore
patent: 6479266 (2002-11-01), Rothe
patent: 6576437 (2003-06-01), Mercurio
patent: 6649654 (2003-11-01), Karin
patent: 6656713 (2003-12-01), Manning
patent: WO 98/36070 (1998-08-01), None
patent: WO 99/38969 (1999-08-01), None
Margottin, GenBank Accession No. Y14153 (1997).
Ohara, EMBL Accession No. AB014596 (1998).
Ishikawa et al., “Prediction of the Coding Sequences of Unidentified Human Genes. X. The Complete Sequences of 100 New cDNA Clones from Brain Which Can Code for Large Proteins in vitro,”DNA Research5:169-176, 1998.
Ohara et al., “Homo sapiensmRNA for KIAA0696 protein, partial cds,” EMBL Database, Accession No. AB014596, 1998.
Margottin et al., “A Novel Human WD Protein, h-βTrCP, that Interacts with HIV-1 Vpu Connects CD4 to the ER Degradation Pathway through an F-Box Motif,”Molecular Cell 1(4):565-574, 1998.
Margottin et al., “A Novel Human WD Protein, h-βTrCP, that Interacts with HIV-1 Vpu Connects CD4 to the ER Degradation Pathway through an F-Box Motif,” Genbank Database, Accession No. Y14153, 1998.
Yaron et al., “Identification of the receptor component of the lκBα-ubiquitin ligase,”Nature 396(6711):590-594, 1998.
Yaron et al., Genbank Database, Accession No. AF101784, 1999.
Yaron et al., Genbank Database, Accession No. AF099932, 1999.
Yaron et al., “Inhibition of NF-κB cellular function via specific targeting of the 1κB-ubiquitin ligase,”EMBO Journal, 16(21):6486-6494, 1997.
Ciechanover, “The Ubiquitin-Proteasome Proteolytic Pathway,”Cell 79: 13-21, 1994.
Margottin et al., “A Novel Human WD Protein, h-βTrCP, that Interacts with HIV-1 Vpu Connects CD4 to the ER Degradation Pathway through an F-Box Motif,”Molecular Cell 1:565-574, 1998.

Affiliated with

Also associated with

Rating

Compounds and methods for modulating activation of NF-κB does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds and methods for modulating activation of NF-κB, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for modulating activation of NF-κB will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4012299